Korro Bio Q3 net loss narrows to $17.55 million

PUBT · 1d ago
Korro Bio Q3 net loss narrows to $17.55 million
  • Korro Bio’s third-quarter 2026 net loss narrowed year over year to $17.55 million.
  • No collaboration revenue was recorded, due to the agreed 12-month pause in the Novo Nordisk collaboration.
  • Cash, cash equivalents and marketable securities totaled $124.8 million at September 30, 2026, supporting a runway into second-half 2028.
  • KRRO-121 dosing began in healthy volunteers in the Phase 1/2 ANCHOR trial, with interim data expected in second-half 2027.
  • A regulatory submission for KRRO-111 is planned for first-half 2027 following preclinical results showing greater than 95% SERPINA1 transcript editing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870897) on November 05, 2026, and is solely responsible for the information contained therein.